See more : Wuhan Citms Technology CO.,LTD. (688038.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Chromocell Therapeutics Corporation (CHRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chromocell Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- L Catterton Asia Acquisition Corp (LCAAU) Income Statement Analysis – Financial Results
- immatics biotechnologies GmbH (IMTXW) Income Statement Analysis – Financial Results
- Malayan Banking Berhad (1155.KL) Income Statement Analysis – Financial Results
- Reach Resources Limited (RR1.AX) Income Statement Analysis – Financial Results
- Thai Union Feedmill Public Company Limited (TFM.BK) Income Statement Analysis – Financial Results
Chromocell Therapeutics Corporation (CHRO)
About Chromocell Therapeutics Corporation
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Metric | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 199.93K |
Cost of Revenue | 2.58M | 391.73K | 209.05K | 138.59K |
Gross Profit | -2.58M | -391.73K | -209.05K | 61.35K |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 30.68% |
Research & Development | 2.58M | 391.73K | 209.05K | 138.59K |
General & Administrative | 4.28M | 1.93M | 629.95K | 1.42M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 4.28M | 1.93M | 629.95K | 1.42M |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 6.86M | 2.32M | 839.00K | 1.55M |
Cost & Expenses | 6.86M | 2.32M | 839.00K | 1.55M |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 518.51K | 140.43K | 253.00 | 1.68K |
Depreciation & Amortization | 0.00 | 690.45K | 839.00K | 1.35M |
EBITDA | -6.86M | -1.63M | 0.00 | 0.00 |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | -677.16% |
Operating Income | -6.86M | -2.32M | -839.00K | -1.35M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | -677.16% |
Total Other Income/Expenses | -518.51K | -140.43K | 243.61K | 693.28K |
Income Before Tax | -7.38M | -2.46M | -595.39K | -660.58K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -330.40% |
Income Tax Expense | 0.00 | -690.45K | -839.00K | -1.35M |
Net Income | -7.38M | -2.46M | -595.39K | -660.58K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | -330.40% |
EPS | -1.28 | -0.43 | -0.10 | -0.11 |
EPS Diluted | -1.28 | -0.43 | -0.10 | -0.11 |
Weighted Avg Shares Out | 5.77M | 5.77M | 5.77M | 5.77M |
Weighted Avg Shares Out (Dil) | 5.77M | 5.77M | 5.77M | 5.77M |
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
IPO Update: Chromocell Therapeutics Seeks $8.7 Million In Micro-IPO
Source: https://incomestatements.info
Category: Stock Reports